Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma

David S. Dickens, Rafal Kozielski, Patrick J. Leavey, Charles Timmons, Timothy P. Cripe

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Purpose: To determine if expression of cyclooxygenase (COX)-2, an inducible enzyme with known tumor-promoting activity, correlates with outcome in pediatric sarcomas. COX-2 overexpression correlates with more aggressive disease in a variety of adult solid tumors. Methods: Archived human osteosarcoma, rhabdomyosarcoma, and Ewing sarcoma tumors were retrospectively evaluated, blinded to outcome, for COX-2 expression by immunohistochemistry and correlated with patient characteristics and survival. Results: COX-2 expression was detected in 94 of 142 (66%) tumors (osteosarcoma, 66/99 [67%]; rhabdomyosarcoma, 21/35 [60%]; Ewing sarcoma, 7/8 [88%]) and 51 of 85 (60%) diagnostic biopsies (osteosarcoma, 26/45 [58%]; rhabdomyosarcoma, 21/35 [60%]; Ewing sarcoma, 4/5 [80%]). COX-2 expression did not vary with clinicopathologic features and was not predictive of prognosis in these cases. Conclusions: This study does not support the use of COX-2 expression as an upfront prognostic variable in patients with osteosarcoma or rhabdomyosarcoma. Results from the small number of patients studied with Ewing sarcoma suggest a similar lack of predictive value for COX-2 expression. However, COX-2 inhibitors are not entirely dependent upon enzyme expression for their antitumor effects; this study does not necessarily preclude the use of COX-2 inhibitors for the treatment of pediatric sarcomas.

Original languageEnglish (US)
Pages (from-to)282-285
Number of pages4
JournalJournal of Pediatric Hematology/Oncology
Volume25
Issue number4
DOIs
StatePublished - Apr 2003

Fingerprint

Rhabdomyosarcoma
Osteosarcoma
Cyclooxygenase 2
Ewing's Sarcoma
Cyclooxygenase 2 Inhibitors
Sarcoma
Pediatrics
Enzymes
Neoplasms
Immunohistochemistry
Biopsy
Survival

Keywords

  • Celecoxib
  • Cyclooxygenase-2
  • Osteosarcoma
  • Rhabdomyosarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma. / Dickens, David S.; Kozielski, Rafal; Leavey, Patrick J.; Timmons, Charles; Cripe, Timothy P.

In: Journal of Pediatric Hematology/Oncology, Vol. 25, No. 4, 04.2003, p. 282-285.

Research output: Contribution to journalArticle

@article{f065bf9a87c945bab99a2e939d2e0779,
title = "Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma",
abstract = "Purpose: To determine if expression of cyclooxygenase (COX)-2, an inducible enzyme with known tumor-promoting activity, correlates with outcome in pediatric sarcomas. COX-2 overexpression correlates with more aggressive disease in a variety of adult solid tumors. Methods: Archived human osteosarcoma, rhabdomyosarcoma, and Ewing sarcoma tumors were retrospectively evaluated, blinded to outcome, for COX-2 expression by immunohistochemistry and correlated with patient characteristics and survival. Results: COX-2 expression was detected in 94 of 142 (66{\%}) tumors (osteosarcoma, 66/99 [67{\%}]; rhabdomyosarcoma, 21/35 [60{\%}]; Ewing sarcoma, 7/8 [88{\%}]) and 51 of 85 (60{\%}) diagnostic biopsies (osteosarcoma, 26/45 [58{\%}]; rhabdomyosarcoma, 21/35 [60{\%}]; Ewing sarcoma, 4/5 [80{\%}]). COX-2 expression did not vary with clinicopathologic features and was not predictive of prognosis in these cases. Conclusions: This study does not support the use of COX-2 expression as an upfront prognostic variable in patients with osteosarcoma or rhabdomyosarcoma. Results from the small number of patients studied with Ewing sarcoma suggest a similar lack of predictive value for COX-2 expression. However, COX-2 inhibitors are not entirely dependent upon enzyme expression for their antitumor effects; this study does not necessarily preclude the use of COX-2 inhibitors for the treatment of pediatric sarcomas.",
keywords = "Celecoxib, Cyclooxygenase-2, Osteosarcoma, Rhabdomyosarcoma",
author = "Dickens, {David S.} and Rafal Kozielski and Leavey, {Patrick J.} and Charles Timmons and Cripe, {Timothy P.}",
year = "2003",
month = "4",
doi = "10.1097/00043426-200304000-00003",
language = "English (US)",
volume = "25",
pages = "282--285",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma

AU - Dickens, David S.

AU - Kozielski, Rafal

AU - Leavey, Patrick J.

AU - Timmons, Charles

AU - Cripe, Timothy P.

PY - 2003/4

Y1 - 2003/4

N2 - Purpose: To determine if expression of cyclooxygenase (COX)-2, an inducible enzyme with known tumor-promoting activity, correlates with outcome in pediatric sarcomas. COX-2 overexpression correlates with more aggressive disease in a variety of adult solid tumors. Methods: Archived human osteosarcoma, rhabdomyosarcoma, and Ewing sarcoma tumors were retrospectively evaluated, blinded to outcome, for COX-2 expression by immunohistochemistry and correlated with patient characteristics and survival. Results: COX-2 expression was detected in 94 of 142 (66%) tumors (osteosarcoma, 66/99 [67%]; rhabdomyosarcoma, 21/35 [60%]; Ewing sarcoma, 7/8 [88%]) and 51 of 85 (60%) diagnostic biopsies (osteosarcoma, 26/45 [58%]; rhabdomyosarcoma, 21/35 [60%]; Ewing sarcoma, 4/5 [80%]). COX-2 expression did not vary with clinicopathologic features and was not predictive of prognosis in these cases. Conclusions: This study does not support the use of COX-2 expression as an upfront prognostic variable in patients with osteosarcoma or rhabdomyosarcoma. Results from the small number of patients studied with Ewing sarcoma suggest a similar lack of predictive value for COX-2 expression. However, COX-2 inhibitors are not entirely dependent upon enzyme expression for their antitumor effects; this study does not necessarily preclude the use of COX-2 inhibitors for the treatment of pediatric sarcomas.

AB - Purpose: To determine if expression of cyclooxygenase (COX)-2, an inducible enzyme with known tumor-promoting activity, correlates with outcome in pediatric sarcomas. COX-2 overexpression correlates with more aggressive disease in a variety of adult solid tumors. Methods: Archived human osteosarcoma, rhabdomyosarcoma, and Ewing sarcoma tumors were retrospectively evaluated, blinded to outcome, for COX-2 expression by immunohistochemistry and correlated with patient characteristics and survival. Results: COX-2 expression was detected in 94 of 142 (66%) tumors (osteosarcoma, 66/99 [67%]; rhabdomyosarcoma, 21/35 [60%]; Ewing sarcoma, 7/8 [88%]) and 51 of 85 (60%) diagnostic biopsies (osteosarcoma, 26/45 [58%]; rhabdomyosarcoma, 21/35 [60%]; Ewing sarcoma, 4/5 [80%]). COX-2 expression did not vary with clinicopathologic features and was not predictive of prognosis in these cases. Conclusions: This study does not support the use of COX-2 expression as an upfront prognostic variable in patients with osteosarcoma or rhabdomyosarcoma. Results from the small number of patients studied with Ewing sarcoma suggest a similar lack of predictive value for COX-2 expression. However, COX-2 inhibitors are not entirely dependent upon enzyme expression for their antitumor effects; this study does not necessarily preclude the use of COX-2 inhibitors for the treatment of pediatric sarcomas.

KW - Celecoxib

KW - Cyclooxygenase-2

KW - Osteosarcoma

KW - Rhabdomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=0242600552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242600552&partnerID=8YFLogxK

U2 - 10.1097/00043426-200304000-00003

DO - 10.1097/00043426-200304000-00003

M3 - Article

C2 - 12679640

AN - SCOPUS:0242600552

VL - 25

SP - 282

EP - 285

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 4

ER -